Protocol revenue is easier to see than protocol margin
Hormone and peptide practices often package care into monthly programs, refill cycles, optimization plans, or bundled protocols. Revenue may be collected cleanly through subscriptions, prepaid programs, or visit-based pricing. The cost side is usually less clean.
A single patient program can include medication, peptides, injection supplies, draw kits, supplements, labs, clinical follow-ups, shipping, cold storage, wasted product, and dose changes. If those costs are not tied to the actual protocol and patient cadence, the practice is reading revenue while guessing at profit.
The operating goal is not to make every protocol rigid. It is to know what the practice used, what it cost, and whether each program is producing the margin the owner expected.
Build each program as a bill of materials
Every hormone, TRT, HRT, peptide, or optimization program should have an expected bill of materials. That includes medications or compounds, syringes, alcohol pads, shipping materials, draw supplies, ancillary supplements, and any included clinical or operational touchpoints that create direct cost.
The bill of materials should be reviewed at the protocol level and adjusted when dosage, concentration, vendor cost, refill cadence, or included services change. A small product cost change can matter when it repeats across every patient in a monthly program.
This gives the owner a baseline margin model before real-world usage creates variance.
Dose changes can reshape the margin curve
Hormone and peptide programs rarely stay static. Patients titrate, pause, restart, add compounds, extend refill intervals, switch product sources, or receive temporary protocol adjustments. Those changes may be clinically appropriate, but they also change direct cost.
A program priced for one dose pattern may become thin if the average patient moves into a higher-cost dose tier without a matching revenue adjustment. The same issue appears when injections, supplies, or follow-up work are bundled too broadly.
Useful reporting separates margin by protocol, dose band, patient cohort, and refill cadence so the practice can see where the economics change as care evolves.
Lot, expiration, and cold-chain discipline protect cash
Hormone and peptide inventory often has expiration, storage, and reorder constraints that make casual tracking expensive. A product can be paid for, received, and stored correctly, then still become a margin loss if it expires before enough profitable visits or refills use it.
Lot and expiration tracking should show which batches are on hand, which are nearing expiration, which patients or protocols consumed each lot, and whether FEFO rotation is actually happening. The same visibility helps practices avoid over-ordering slow-moving protocols.
Inventory control matters because product sitting in a refrigerator is not profit. It becomes profit only when it is consumed in a service or program that protects margin.
Bundles need revenue allocation, not just a package price
Many optimization practices sell programs that combine consults, products, labs, follow-ups, refills, and support. A single collected price can hide which parts of the program are profitable and which parts are carrying too much cost.
Revenue allocation helps the owner understand product COGS against the correct part of the program. Without it, a high-ticket protocol may look strong while expensive refills, included supplies, or unpriced add-ons quietly consume contribution margin.
The useful view connects patient payments, product usage, lot cost, waste, discounts, and provider activity across the life of the program.
Provider and location patterns need review
Two providers can run the same peptide or hormone program with different refill timing, product choices, add-on patterns, waste, and discounting. Two locations can carry different inventory levels and expiration risk. Those differences become material when the practice scales.
Provider-level and location-level margin reporting keeps those patterns visible without turning every decision into a manual audit. The owner can coach protocol discipline, adjust ordering, and decide whether a service line is ready to grow.
Otzaro is built around this connection: product movement, point-of-service COGS, ordering, batching, provider activity, and profit intelligence in one operating layer alongside the systems the practice already uses.
Review protocols before growth magnifies the gaps
The time to inspect protocol profitability is before a program expands through ads, memberships, referrals, or additional providers. Growth multiplies both good economics and weak economics.
A practical cadence is weekly review for stockouts, expiring lots, unusual usage, and reorder needs; monthly review for protocol margin, dose-band margin, bundle economics, and provider variance; and quarterly review for pricing, vendor terms, and service mix decisions.
When product cost drives the model, protocol growth should be governed by margin data instead of confidence from top-line revenue alone.
A hormone or peptide program is ready to scale when the practice can answer
What products, supplies, labs, and included touchpoints belong in the protocol cost model?
How does margin change by dose band, refill cadence, vendor cost, and patient cohort?
Which lots are nearing expiration, and which protocols can use them profitably?
Which providers or locations are changing product usage, discounts, waste, or reorder needs?
Which programs should be repriced, narrowed, paused, or expanded based on actual margin?
FAQ
How should hormone and peptide practices calculate protocol profitability?
Start with collected revenue, then subtract the actual product COGS, supplies, bundled direct costs, waste, discounts, and included touchpoints tied to each patient program or refill cycle. Review the result by protocol, dose band, provider, and month.
Why does lot tracking matter for peptide and hormone clinics?
Lot tracking connects product on hand to expiration dates, patient usage, reorder timing, and margin. It helps operators prevent avoidable waste and understand which batches were consumed by which protocols.
Can monthly wellness programs hide margin problems?
Yes. Monthly programs can make revenue predictable while hiding higher product usage, included supplies, refill changes, discounting, or expired inventory. Margin should be reviewed when the protocol is fulfilled, not only when payment is collected.
Does Otzaro replace an EMR for hormone or peptide practices?
No. Otzaro works alongside the clinical and scheduling systems the practice already uses. It adds the profit, inventory, ordering, batching, and COGS visibility those systems usually do not provide.